WAVE Life Sciences Ltd. (NASDAQ:WVE) to Release Quarterly Earnings on Monday
WAVE Life Sciences Ltd. (NASDAQ:WVE) will announce its earnings results on Monday, August 14th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.
WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.80 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%. On average, analysts expect WAVE Life Sciences to post $-3.31 EPS for the current fiscal year and $-3.27 EPS for the next fiscal year.
Shares of WAVE Life Sciences Ltd. (NASDAQ WVE) opened at 20.10 on Monday. WAVE Life Sciences Ltd. has a 12 month low of $15.15 and a 12 month high of $40.15. The company has a 50-day moving average of $19.11 and a 200 day moving average of $23.57. The company’s market capitalization is $557.11 million.
In related news, insider Michael A. Panzara sold 7,414 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the transaction, the insider now owns 15,336 shares in the company, valued at approximately $255,651.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 53.00% of the stock is currently owned by corporate insiders.
Several equities research analysts have issued reports on WVE shares. ValuEngine lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of WAVE Life Sciences in a report on Wednesday, April 26th. Zacks Investment Research lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $40.00 target price on shares of WAVE Life Sciences in a report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $42.00.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.